Overview

Study to Determine the Efficacy&Safety of ARV-1801/ACG-701 for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Status:
Not yet recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of an oral ARV-1801/ACG-701 plus optimized background therapy (OBT) compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with Cystic Fibrosis-related pulmonary exacerbations.

Phase:

Phase 2

Details

Lead Sponsor:

Aceragen

Treatments:

Fusidic Acid